BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 18650431)

  • 1. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology.
    Cole SL; Vassar R
    J Biol Chem; 2008 Oct; 283(44):29621-5. PubMed ID: 18650431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BACE1 structure and function in health and Alzheimer's disease.
    Cole SL; Vassar R
    Curr Alzheimer Res; 2008 Apr; 5(2):100-20. PubMed ID: 18393796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of cleavage at β'-site contributes to apparent increase in β-amyloid peptide (Aβ) secretion by β-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein.
    Vetrivel KS; Barman A; Chen Y; Nguyen PD; Wagner SL; Prabhakar R; Thinakaran G
    J Biol Chem; 2011 Jul; 286(29):26166-77. PubMed ID: 21642424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
    Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
    J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
    Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
    J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
    Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
    Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
    Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
    J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
    Kimura A; Hata S; Suzuki T
    J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
    Sadleir KR; Eimer WA; Cole SL; Vassar R
    Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
    McConlogue L; Buttini M; Anderson JP; Brigham EF; Chen KS; Freedman SB; Games D; Johnson-Wood K; Lee M; Zeller M; Liu W; Motter R; Sinha S
    J Biol Chem; 2007 Sep; 282(36):26326-34. PubMed ID: 17616527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
    Tomita T
    Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
    Chiocco MJ; Kulnane LS; Younkin L; Younkin S; Evin G; Lamb BT
    J Biol Chem; 2004 Dec; 279(50):52535-42. PubMed ID: 15452128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.
    Buggia-Prevot V; Sevalle J; Rossner S; Checler F
    J Biol Chem; 2008 Apr; 283(15):10037-47. PubMed ID: 18263584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and biology of β-secretase.
    Kandalepas PC; Vassar R
    J Neurochem; 2012 Jan; 120 Suppl 1():55-61. PubMed ID: 22122287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.